Zoledronate and ibandronate treatments provide a significant improvement in BMD values in osteoporosis patients

Journal Title: Orthopaedics and Surgical Sports Medicine - Year 2018, Vol 1, Issue 3

Abstract

Objective: In this study, we aimed to make a comparative analysis of short term clinical effectivity and side effects of intravenous zoledronate administration as single dose yearly and intravenous ibandronate administration as four doses per year. Methods: The patients whom were included in our study had osteoporosis according to WHO criteria and were treated with either parenteral zoledronate or ibandronate. 43 patients were treated with single dose of 5mg intravenous zolendronat which was applied once in a year; whereas in 39 patients were treated with 3 mg intravenous ibandronate which was applied four times in a year in three months intervals. Biochemical tests were performed in all patients before intravenous drug infusion. Side effects during drug administration and also in the first three months of the treatment were noted for all patients. Clinical effectivity was analyzed according to changes in bone mineral density (BMD) at the end of two year after treatment. Results: Eighty-two patients who were followed-up and evaluated for the effectivity and side effects of the treatment were included in our study. The compliance of patients were 100% in both groups. Mean age was 75.23±6.9 years and mean body mass index (BMI) was 26.94±7.2. In zoledronate group in which there were 23 females and 20 males. Mean age was 73.64±8.7 years and mean BMI was 27.34±4.4. In ibandronate group in which there were 39 females. There were no statistically significant differences between the groups in terms of gender (p=0.000) Mean age, BMI and rate of diagnosed side effects were not statistically significant in between the groups. According to a one-year follow-up in both groups comparison with before application had a statistically significant increase in BMD (p<0.01). However, a one-year follow-up between the two groups in terms of mean values of bone mineral density did not differ significantly (p>0.05). Conclusion: Choice of medical treatment is decided according to bone mineral density and personal risk factors in osteoporosis. Parenteral agents in the treatment of osteoporosis may be the preferred choice for the patients with comorbid diseases, using multiple drug therapies, or having trouble in using oral drug therapy. However, it should always be kept in mind that drug related side effects may be seen more commonly with parenteral agents. Clinicians should be aware of the probable side effects during and after app

Authors and Affiliations

Jaxon Dawson

Keywords

Related Articles

DO DIFFERENT WOUND DRESSINGS AFTER TOTAL JOINT ARTHROPLASTY MAKE A DIFFERENCE?Do Different Wound Dressings After Total Joint Arthroplasty Make A Difference?

Total joint arthroplasty (TJA) has excellent outcomes in the majority of patients. However, periprosthetic joint infection (PJI) remains one of the most frequent and devastating complications. To minimize this risk, orth...

Massive Thrombophlebitis as a Complication after Carpal Tunnel Release: Comorbid Factors?

Seven days before the patient had an endoscopic carpal tunnel release under locoregional anesthesia. We performed a single-portal technique as described by Agee. The patient was positioned in dorsal decubitus with this r...

The TCI is a new index representing the relationship between the smaller trochlear and larger capitellar angles of the measured elbow

Background: In children supracondylar fracture of the humorous is one of the most common fractures in the first decade of life. This study was conducted to establish the efficacy and the accuracy of a new own method for...

Iatrogenic vertebral artery injury during cervical spine surgery

Osteoblastomas are rare benign, primary bone tumors which frequently arise in the spine. Patients often present with dull back pain sometimes associated with painful scoliosis. Neurological manifestations such as radicul...

Methodical clinical measurement of knee deformity

The recognition of the pattern and severity of deformity in knee osteoarthritis has important implications in its management and prognosis. A number of methods can be used to assess and measure the coronal and sagittal k...

Download PDF file
  • EP ID EP661192
  • DOI 10.31579/2641-0427/013
  • Views 51
  • Downloads 0

How To Cite

Jaxon Dawson (2018). Zoledronate and ibandronate treatments provide a significant improvement in BMD values in osteoporosis patients. Orthopaedics and Surgical Sports Medicine, 1(3), 1-5. https://europub.co.uk/articles/-A-661192